RAPP
Rapport Therapeutics, Inc. Common Stock NASDAQ Listed Jun 7, 2024$37.34
+1.27%
vs $36.87
Mkt Cap $1.8B
52w Low $10.88
91.1% of range
52w High $39.93
50d MA $36.72
200d MA $29.91
P/E (TTM)
—
EV/EBITDA
—
P/B
3.6x
Debt/Equity
0.0x
ROE
-23.0%
P/FCF
-19.9x
RSI (14)
43.40
ATR (14)
$2.31
Beta
1.10
50d MA
$36.72
200d MA
$29.91
Avg Volume
328.9K
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
1325 Boylston Street · Boston, DE 02110 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 37.06 | +1.2% | +7.7% | -4.7% | +1.0% | -3.1% | +2.3% | — |
| Mar 10, 2026 | AMC | -0.65 | -0.72 | -10.8% | 29.63 | +0.8% | +3.1% | -6.1% | -2.9% | -0.8% | +0.4% | — |
| Nov 6, 2025 | AMC | -0.77 | -0.71 | +7.8% | 25.36 | +4.3% | +1.2% | -2.9% | +2.3% | -1.3% | -2.0% | — |
| Aug 7, 2025 | AMC | -0.87 | -0.75 | +13.8% | 15.41 | +0.0% | -5.6% | -1.9% | +8.8% | +0.4% | -4.2% | — |
| May 8, 2025 | AMC | -0.77 | -0.68 | +11.7% | 10.65 | -0.2% | -3.8% | +2.1% | -4.6% | -3.6% | +1.4% | — |
| Mar 11, 2025 | AMC | -0.62 | -0.57 | +8.1% | 8.96 | +5.4% | +11.7% | +0.1% | +4.9% | -3.1% | -2.5% | — |
| Nov 7, 2024 | AMC | -0.57 | -0.50 | +12.3% | 26.90 | +0.0% | -0.8% | +0.8% | -9.8% | -9.9% | +0.6% | — |
| Aug 8, 2024 | AMC | -0.68 | -1.70 | -150.0% | 18.56 | -4.4% | +2.7% | -4.1% | +11.4% | +0.2% | -0.1% | — |
| Mar 31, 2024 | AMC | — | -0.12 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.07 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.05 | — | — | — | — | — | — | — | — | — |
| Jun 29, 2023 | AMC | — | -0.03 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.03 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Truist | Reiterates | Buy | $56 | $35.18 | $35.47 | +0.8% | -2.3% | +3.9% | +2.7% | +2.8% | +5.3% |
| Apr 22 | BTIG | Maintains | Buy → Buy | — | $36.95 | $37.38 | +1.2% | -0.5% | -1.1% | +0.6% | -3.2% | -4.7% |
| Mar 11 | BTIG | Maintains | Buy → Buy | — | $29.63 | $29.86 | +0.8% | +3.1% | -6.1% | -2.9% | -0.8% | +0.4% |
| Mar 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $29.63 | $29.86 | +0.8% | +3.1% | -6.1% | -2.9% | -0.8% | +0.4% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.16 | $30.68 | +1.7% | -5.0% | +0.1% | +0.4% | +5.2% | -2.2% |
| Dec 8 | BTIG | Maintains | Buy → Buy | — | $29.50 | $30.18 | +2.3% | +2.2% | -5.0% | +0.1% | +0.4% | +5.2% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $25.36 | $26.46 | +4.3% | +1.2% | -2.9% | +2.3% | -1.3% | -2.0% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.36 | $38.42 | +167.5% | +119.2% | -10.9% | -20.1% | +3.6% | +2.4% |
| Jul 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.04 | $12.04 | +0.0% | +4.8% | +11.0% | +9.8% | -5.1% | +0.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | Third Rock Ventures V, L.P. | — | Sell | 18,572 | $40.05 | $744K | 6,280,525 | +0.03% | +1.32% |
| May 11, 2026 | Third Rock Ventures V, L.P. | — | Sell | 133,618 | $40.24 | $5.4M | 6,299,097 | -0.34% | +3.93% |
| May 8, 2026 | Third Rock Ventures V, L.P. | — | Sell | 5,018 | $40.31 | $202K | 6,432,715 | -3.10% | -5.10% |
| May 7, 2026 | Third Rock Ventures V, L.P. | — | Sell | 271,495 | $40.12 | $10.9M | 6,437,733 | -3.10% | -5.10% |
8-K
Rapport Therapeutics, Inc. -- 8-K Filing
Jun 10
8-K · 8.01
!! High
Rapport Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Rapport Therapeutics announced positive Phase 2a data for RAP-219 in focal onset seizures, showing the drug reduced long episodes—an objective biomarker with 90% concordance to clinical seizures—supporting further development.
Apr 21
8-K
Unknown — 8-K Filing
Rapport's $490.5 million cash runway extending to mid-2029 provides sufficient capital for RAP-219 development across multiple indications, reducing near-term financing risk and allowing investors to evaluate clinical progress before potential dilution.
Mar 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 7,168,939 | $224M | Added | Mar 2026 |
| 2 | Johnson & Johnson | 1,784,517 | $56M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,325,082 | $41M | New | Mar 2026 |
| 4 | Capital World Investors | 536,607 | $17M | New | Mar 2026 |
| 5 | Morgan Stanley | 420,662 | $13M | Reduced | Dec 2025 |
| 6 | Vanguard Portfolio Management Llc | 320,909 | $10M | New | Mar 2026 |
| 7 | Millennium Management | 319,552 | $10M | Added | Mar 2026 |
| 8 | Northern Trust Corp | 237,992 | $7M | Added | Mar 2026 |
| 9 | Ensign Peak Advisors, Inc | 194,200 | $6M | — | Mar 2026 |
| 10 | D.e. Shaw & Co | 175,449 | $5M | Reduced | Mar 2026 |
| 11 | Invesco Ltd. | 171,757 | $5M | Reduced | Mar 2026 |
| 12 | Ubs Group Ag | 151,758 | $5M | Reduced | Mar 2026 |
| 13 | Prudential Financial Inc | 114,815 | $4M | Reduced | Mar 2026 |
| 14 | Swedbank Ab | 113,200 | $4M | — | Mar 2026 |
| 15 | Bank Of America Corp /de/ | 110,826 | $3M | Added | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 72,319 | $2M | Reduced | Mar 2026 |
| 17 | Nuveen, Llc | 71,508 | $2M | Added | Mar 2026 |
| 18 | Voya Investment Management Llc | 66,149 | $2M | Added | Dec 2025 |
| 19 | Citigroup Inc | 56,484 | $2M | Added | Dec 2025 |
| 20 | Bnp Paribas Financial Markets | 35,952 | $1M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.75B
Enterprise Value
$1.27B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.02x
P/B
3.62x
P/S
87.71x
P/FCF
-19.91x
EV/EBITDA
—
Shares Out
47.0M
Financials (TTM)
Revenue
$20.0M
Net Income
-$107.3M
EBITDA
-$118.1M
Free Cash Flow
-$88.1M
Op Cash Flow
-$87.5M
EPS Basic
$-2.86
EPS Diluted
$-2.60
EPS Forward
$-3.37
Gross Margin
95.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$512.4M
Total Liab.
$27.8M
Total Equity
$484.7M
Cash
$490.5M
LT Debt
$8.7M
Book Value/Sh
$10.32
Debt/Equity
0.02x
Current Ratio
26.17
Quick Ratio
26.17
Returns & Growth
ROE
-23.0%
ROA
-21.8%
ROIC
-25.2%
Rev Growth YoY
+0.0%
EPS Growth YoY
-652.6%
Price Returns
2W
+4.1%
1M
+19.2%
3M
+36.1%
6M
+33.0%
12M
+377.6%
Technicals
52W High
$39.93
52W Low
$10.88
50d MA
$36.72
200d MA
$29.91
RSI (14)
43.40
ATR (14)
$2.31
Beta
1.10
Avg Volume
329K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$49.00
High
$66.00
Low
$40.00
Median
$45.00
Data updated apr 26, 2026 9:53pm
· Source: financialmodelingprep.com